Its aberrant activation is strongly associated with tumor progression andmetastasis in several malignancies, including breast, ovarian, prostate and pancreatic cancers [2].Overexpression of FAK has been correlated with poor prognosis, increased invasiveness, and resistance to therapy [3].As such, FAK represents an attractive therapeutic target in oncology. This evidence concerns the gene PTK2 and familial pancreatic carcinoma.